knowledge -WSS

knowledge

author：entertainment 2025-09-30 16:28:08 - browse：914

Light hits on the portrait of George Washington on a one dollar bill. The portrait is surrounded by white and red tablets coming out of a pill bottle, as well as some coins — coverage from STAT — Adobe

WASHINGTON — Pharmaceutical companies are doing anything they can to stop President Biden’s Medicare program from being able to negotiate prices for their products, including suing the government. Experts say their efforts might actually benefit Biden by reminding voters that he’s taking on big drug companies.

When Democrats passed a law directing Medicare to negotiate drug prices, it was considered a major achievement. The new law, two decades in the making, gives Biden an accomplishment to both tout for himself and criticize Republicans for opposing — no Republicans voted to let Medicare negotiate drug prices.

Medicare price negotiation is popular with voters, as are the law’s price-inflation limits, and it includes additional, direct benefits for older adults that are easy to understand. It caps annual out-of-pocket retail-drug spending for seniors and people with disabilities, and it caps their monthly spending on insulin at $35.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： The best solution to the drug shortages problem

WSS

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Police still searching for prisoner who escaped from NYC hospital

The best solution to the drug shortages problem

A disappointing year of Humira biosimilars

Readout LOUD podcast: How biotech is using artificial intelligence

Police still searching for prisoner who escaped from NYC hospital

knowledge

knowledge

focus

Anesthesiologist group: stop taking Ozempic before surgery

Biden report: The neurospychology of memory and aging

Heart attack and stroke risk calculators need revising

How to use technology to prevent future drug shortages

Duchenne breakthrough therapy leaves behind pioneering families

For Medicare Advantage, Democrats want stronger protections around AI

In Memoriam: Notable people who died in 2023

Wegovy trial has doctors encouraged over new possibilities

Sports medicine is finally prioritizing gender equality

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

leisure time

The Readout: Gilead, Bernie Sanders, and other pharma news

For Cytokinetics, FDA rejection of heart drug would help, not hinder

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

South Korea throws huge K

Drastic changes should bring profitability, startup health insurers say

leisure time

entertainment

entertainment

hotspot